Us Congress 2025-2026 Regular Session

House Energy and Commerce Committee Bills & Legislation (Page 31)

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1922

Introduced
3/6/25  
Ensuring Access to Essential Drugs Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1901

Introduced
3/6/25  
CHIPP Act Children’s Health Insurance Program Permanency Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1961

Introduced
3/6/25  
CARE Act Coordinated Agency Response Enhancement Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1902

Introduced
3/6/25  
HERO Act Helping Emergency Responders Overcome Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1915

Introduced
3/6/25  
Refer
3/6/25  
Stop the Cartels Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1896

Introduced
3/6/25  
Renewable Fuel for Ocean-Going Vessels Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1966

Introduced
3/6/25  
Mamas and Babies in Underserved Communities Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1899

Introduced
3/6/25  
Audio-Only Telehealth Access Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2115

Introduced
3/14/25  
Ending China’s Unfair Advantage Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2813

Introduced
4/10/25  
Small Modular Reactor Commercialization Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2532

Introduced
4/1/25  
To prohibit certain removals of employees of the Department of Health and Human Services and sub-agencies and operating divisions thereof, and for other purposes.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2587

Introduced
4/1/25  
Youth Mental Health Research Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2554

Introduced
4/1/25  
Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2542

Introduced
4/1/25  
Old Drugs, New Cures Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2529

Introduced
4/1/25  
Convenient Contraception Act